Survivorship after Hodgkin lymphoma and the right to be forgotten.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
25 Jun 2024
25 Jun 2024
Historique:
medline:
15
7
2024
pubmed:
15
7
2024
entrez:
15
7
2024
Statut:
aheadofprint
Résumé
The significantly improved survivorship in Hodgkin lymphoma is fraught with challenges, including persistent symptoms, secondary health complications, and socio-professional obstacles. This review highlights the need for comprehensive survivorship care plans that include detection of relapse, assessment of long-term side effects, screening for secondary cancers, psychological support, and assistance with socio-professional integration. Cardiovascular diseases, secondary malignancies and other associated risks remains an important problem related to the effective treatment of patients with Hodgkin lymphoma. Furthermore, fertility concerns and endocrine disorders remain prevalent issues posttreatment. An optimal evaluation of the risks before and after treatment is essential to reduce the impact of these side effects on quality of life. Addressing the socio-professional reintegration of survivors, the concept of the 'Right to be forgotten' emerges as a critical consideration. This principle seeks to eliminate discrimination against cancer survivors in accessing financial services and aims for legislative changes to ensure that past cancer diagnosis does not unfairly affect survivors' futures. Implementation of this 'Right to be forgotten' in the legislature, is currently underway in European countries. The focus of survivorship care has shifted towards the holistic management of these long-term outcomes. Quality of life for Hodgkin lymphoma survivors is affected by various treatment-related factors, with evidence suggesting that physical, psychological and socio-professional domains remain impacted years after treatment.
Identifiants
pubmed: 39007329
doi: 10.1097/CCO.0000000000001072
pii: 00001622-990000000-00188
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Shapiro CL. Cancer survivorship. N Engl J Med 2018; 379:2438–2450.
European Commission: A Cancer Plan for Europe [cited 13 March 2023]. Available at: https://commission.europa.eu/strategy-and-policy/priorities-2019-2024/promoting-our-european-way-life/european-health-union/cancer-plan-europe_en. [Accessed 13 March 2024].
Conquering Cancer: mission possible: interim report of the mission board for cancer (European Commission) [cited 10 March 2023]. Available at: https://op.europa.eu/en/web/eu-law-and- publications/publication-detail/-/publication/d0235612-b68a-11ea-bb7a-01aa75ed71a1.
Denlinger CS, Sanft T, Moslehi JJ, et al. NCCN guidelines insights: survivorship, version 2.2020. J Natl Compr Cancer Netw 2020; 18:1016–1023.
The surveillance, epidemiology, and end results (SEER). [cited 13 February 2023]. Available at: https://seer.cancer.gov/statfacts/html/hodg.html.
Eichenauer DA, Aleman BMP, André M, et al. ESMO Guidelines Committee Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29:iv19–iv29.
American Cancer Society. Key statistics for Hodgkin lymphoma. Available at: https://www.cancer.net/cancer-types/lymphoma-hodgkin/statistics. [Accessed 13 March 2024].
Sasse S, Bröckelmann PJ, Goergen H, et al. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials. J Clin Oncol 2017; 35:1999–2007.
Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2017; 390:2790–2802.
von Tresckow B, Kreissl S, Goergen H, et al. German Hodgkin Study Group Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol 2018; 5:e462–e473.
Federico M, Fortpied C, Stepanishyna Y, et al. Long-term follow-up of the response-adapted intergroup EORTC/LYSA/FIL H10 Trial for localized Hodgkin lymphoma. J Clin Oncol 2024; 42:19–25.
Van Leeuwen F, van’t Veer M, Aleman BMP, et al. A Dutch nationwide survivorship care program for Hodgkin lymphoma survivors. J Clin Oncol 2016; 34:6–16.
Bari A, Gerardi C, Allocati E, et al. Clinical management of long-term survivors after classical Hodgkin lymphoma and diffuse large B-cell lymphoma. Cancers (Basel) 2022; 14:5960.
Arndta V, Koch-Gallenkampa L, Jansen L, et al. Quality of life in long-term and very long-term cancer survivors versuspopulation controls in Germany. Acta Oncol 2017; 56:190–197.
International Health Conference Constitution of the World Health Organization. 1946. Bull World Health Organ 2002; 80:983–984.
Kreissl S, Müller H, Goergen H, et al. Health-related quality of life in patients with Hodgkin lymphoma: a longitudinal analysis of the German Hodgkin study group. J Clin Oncol 2020; 38:2839–2848.
Rosenthal A. Quality of life and survivorship in lymphoma. Curr Oncol Rep 2022; 24:1113–1120.
Hlubocky FJ, Webster K, Beaumont J, et al. A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the national comprehensive cancer network-functional assessment of cancer therapy - lymphoma symptom index. Leuk Lymphoma 2013; 54:1942–1946.
Moinpour CM, Unger JM, Ganz PA, et al. Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 2017; 11:32–40.
Behringer K, Goergen H, Müller H, et al. Cancer-related fatigue in patients with and survivors of Hodgkin lymphoma: the impact on treatment outcome and social reintegration. J Clin Oncol 2017; 34:4329–4338.
Mian H, Ringash J, Meyer R, et al. Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6. Support Care Cancer 2023; 31:256.
Minoia C, Gerardi C, Allocati E, et al. The impact of healthy lifestyles on late sequelae in classical hodgkin lymphoma and diffuse large B-cell lymphoma survivors. A systematic review by the Fondazione Italiana Linfomi. Cancers (Basel) 2021; 13:3135.
Ng AK, Li S, Recklitis C, et al. A comparison between long-term survivors of Hodgkin's disease and their siblings on fatigue level and factors predicting for increased fatigue. Ann Oncol 2005; 16:1949–1955.
Oldervoll LM, Loge JH, Kaasa S, et al. Physical activity in Hodgkin's lymphoma survivors with and without chronic fatigue compared with the general population – a cross-sectional study. BMC Cancer 2007; 7:210.
Linendoll N, Saunders T, Burns R, et al. Health-related quality of life in Hodgkin lymphoma: a systematic review. Health Qual Life Outcomes 2016; 14:114.
Gerardi C, Allocati E, Minoia C, et al. Long-term follow-up of classical Hodgkin lymphoma and diffuse large B-cell lymphoma survivors: aims and methodological approach for Fondazione Italiana Linfomi systematic reviews. Cancers 2021; 13:2976.
Ferdinandus J, Müller H, Damaschin C, et al. Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin's lymphoma: results from the randomized international GHSG HD18 trial. Ann Oncol 2024; 35:276–284.
Magyari F, Virga I, Simon Z, et al. Assessment of cognitive function in long-term Hodgkin lymphoma survivors, results based on data from a major treatment center in Hungary. Support Care Cancer 2022; 30:5249–5258.
Trachtenberg E, Mashiach T, Ben Hayun R, et al. Cognitive impairment in Hodgkin lymphoma survivors. Br J Haematol 2018; 182:670–678.
Fayette D, Juríčková V, Kozák T, et al. Cognitive impairment associated with Hodgkin's lymphoma and chemotherapy. Neuroscience Letters 2023; 797:137082.
André M, Carde P, Viviani S, et al. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: a pooled analysis of four randomized trials. Cancer Med 2020; 9:6565–6575.
Houlihan OA, Ntentas G, Cutter DJ, et al. Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma. Clin Transl Oncol 2023; 25:1368–1377.
Shbib Dabaja B, Boyce-Fappiano D, Dong W, et al. Second malignancies in patients with Hodgkin's Lymphoma: half a century of experience. Clin Transl Radiat Oncol 2022; 13:64–69.
Moskowitz CS, Ronckers CM, Joanne F, et al. Development and validation of a breast cancer risk prediction model for childhood cancer survivors treated with chest radiation: a report from the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts. J Clin Oncol 2021; 39:3012–3021.
Wong S. Best practice & research clinical haematology: screening for breast cancer in Hodgkin lymphoma survivors. Res Clin Haematol 2023; 36:101525.
Ng AK, Garber JE, Diller LR, et al. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol 2013; 31:2282–2288.
Mulder RL, Hudson MM, Bhatia S, et al. Updated breast cancer surveillance recommendations for female survivors of childhood adolescent, and young adult cancer from the international guideline harmonization group. J Clin Oncol 2020; 38:4194–4207.
Eisenberg ER, Weiss A, Prakash I, et al. Surgical management and contralateral breast cancer risk in women with history of radiation therapy for Hodgkin lymphoma: results from a population-based cohort. Ann Surg Oncol 2022; 29:6673–6680.
Wong SM, Ajjamada L, Weiss AC, et al. Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: results from a population-based cohort. Cancer 2022; 128:1365–1372.
Ykema BLM, Gini A, Rigter LS, et al. Cost-effectiveness of colorectal cancer surveillance in Hodgkin lymphoma survivors treated with procarbazine and/or infradiaphragmatic radiotherapy. Cancer Epidemiol Biomarkers Prev 2022; 31:2157–2168.
Wong F. Risk and outcome of second primary malignancy in patients with classical Hodgkin lymphoma. Medicine (Baltimore) 2022; 101:31967.
Van Leeuwen FE, Ng AK. Late sequelae in Hodgkin lymphoma survivors. Hematol Oncol 2017; 35:60–66.
Oliva S, Puzzovivo A, Gerardi C, et al. Late cardiological sequelae and long-term monitoring in classical Hodgkin lymphoma and diffuse large B-cell lymphoma survivors: a systematic review by the Fondazione Italiana Linfomi. Cancers (Basel) 2022; 14:61.
Lu Z, Teng Y, Ning X, et al. Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors. Cancer 2022; 128:3330–3339.
de Vries S, Haaksma ML, Jóźwiak K, et al. Development and validation of risk prediction models for coronary heart disease and heart failure after treatment for Hodgkin lymphoma. J Clin Oncol 2023; 41:86–95.
Loap P, Orlandi E, De Marzi L, et al. Cardiotoxicity model-based patient selection for Hodgkin lymphoma proton therapy. Acta Oncol 2022; 61:979–986.
Polomski EAS, Heemelaar JC, de Graaf MA, et al. Relation between coronary artery calcium score and cardiovascular events in Hodgkin lymphoma survivors: a cross-sectional matched cohort study. Cancers (Basel) 2023; 15:5831.
Macklin-Dohertya A, Jonesc M, Coulsonc P, et al. Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatment. Leukemia Lymphoma 2022; 63:562–572.
Ng AK, van Leeuwen FE. Hodgkin lymphoma: late effects of treatment and guidelines for surveillance. Semin Hematol 2016; 53:209–215.
Kiserud CE, Seland M, Holte H, et al. Fatigue in male lymphoma survivors differs between diagnostic groups and is associated with latent hypothyroidism. Acta Oncol 2015; 54:49–59.
Cattoni A, Molinari S, Riva B, et al. Thyroid function disorders and secondary cancer following haematopoietic stem cell transplantation in pediatrics: state of the art and practical recommendations for a risk-based follow-up. Front Endocrinol (Lausanne) 2022; 13:1064146.
Di Molfetta S, Daniele A, Gerardi C3, et al. Late endocrine and metabolic sequelae and long-term monitoring of classical Hodgkin lymphoma and diffuse large B-cell lymphoma survivors: a systematic review by the Fondazione Italiana Linfomi. Cancers (Basel) 2022; 14:1439.
Drechsel KCE, Pilon MCF, Stoutjesdijk F, et al. Reproductive ability in survivors of childhood, adolescent, and young adult Hodgkin lymphoma: a review. Hum Reprod Update 2023; 29:486–517.
Entrop JP, Weibull CE, Smedby KE, et al. Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway-A population-based matched cohort study. Int J Cancer 2023; 153:723–731.
National Comprehensive Cancer Network (NCCN) Guidelines, version 2.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/hodgkin_blocks.pdf. [Accessed 8 March 2024]
Eikeland SA, Smeland KB, Simensen VC, et al. Chronic fatigue in long-term survivors of Hodgkin's lymphoma after contemporary risk-adapted treatment. Acta Oncol 2023; 62:80–88.
Amatya B, Khan F, Lew TE, et al. Rehabilitation in patients with lymphoma: an overview of systematic reviews. J Rehabil Med 2021; 53:jrm00163.
Zegers AD, Coenen P, Bültmann U, et al. Supporting participation in paid work of cancer survivors and their partners in the Netherlands: protocol of the SusTained Employability in cancer Patients and their partner (STEPS) multicentre randomized controlled trial and cohort study. BMC Public Health 2021; 21:1844.
Zegers AD, Coenen P, Bültmann U, et al. Tailoring work participation support for cancer survivors using the stages of change: perspectives of (healthcare) professionals and survivors. J Cancer Surviv 2023; 17:706–719.
Ciavarella S, Minoia C, Quinto AM, et al. Improving provision of care for long-term survivors of lymphoma. Clin Lymphoma Myeloma Leuk 2017; 17:e1–e9.
Saul H, Liu L, Meunier F. Call for action to end discrimination against cancer survivors. J Can Pol 2018; 17:1–3.
Scocca G, Meunier F. A right to be forgotten for cancer survivors. A legal development expected to reflect the medical progress in the fight against cancer. J Can Pol 2020; 25:1–4.
Lawler M, De Lorenzo F, Lagergren P, et al. European Academy of Cancer Sciences Challenges and solutions to embed cancer survivorship research and innovation within the EU cancer Mission. Mol Oncol 2021; 15:1750–1758.
Scocca G, Meunier F. Towards an EU legislation on the right to be forgotten to access to financial services for cancer survivors. Eur J Cancer 2022; 162:133–137.
Ending discrimination against cancer survivors. Available at: http://endingdiscrimination-cancersurvivors.eu. [Accessed 21 March 2024]
Damlaj M, El Fakih R, Hashmi SK. Evolution of survivorship in lymphoma, myeloma and leukemia: metamorphosis of the field into long term follow-up care. Blood Rev 2019; 33:63–73.
Majhail NS. Long-term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther 2017; 10:220–227.
Krolak D, Collins B, Weiss L, et al. Cognitive function and its relationship to other psychosocial factors in lymphoma survivors. Support Care Cancer 2017; 25:905–913.